Clinical Trials Browser

Phase 1/2 × pasireotide × Breast × Clear all

NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Phase 1/2 Terminated

9 enrolled 3 charts

Carcinoma, Intraductal, Noninfiltrating